dev home - Alloy Therapeutics

Our ecosystem model transforms drug discovery.

We are a biotechnology ecosystem company.

We offer our technologies and capabilities to the entire drug discovery community—from academic scientists, small and medium biotech, to the largest biopharma—on affordable, non-exclusive terms. This network of collaboration among drug discovery teams creates innovations that are then widely distributed to benefit all.

See Case Studies

We empower discovery across 6 biologic modalities

We’ve grown from our original platform for human monoclonal antibody discovery, the ATX-Gx, to support a spectrum of biologics. Discovery groups find the best drug against their target and develop innovative new therapeutic formats.

ANTIBODIES

TCRS

GENETIC MEDICINES

PEPTIDES

CELL THERAPIES

DELIVERY

We make foundational drug discovery capabilities available to all.

We reinvest 100% of our revenue into innovation and access to innovation to continually improve our offering for partners. Our white glove model includes:

PLATFORMS

SERVICES

SUBSCRIPTIONS

Access to enabling technologies

We acquire and develop pre-competitive discovery platforms and license them to the global drug discovery community at groundbreaking terms.

Chat with Business Development

Dig into:

ATX-Gx

Augmenting your capacity

Our discovery services team acts as an extension of yours, deploying our proprietary and industry standard suite of technologies to find you the best candidate against your target.

Meet the Venture Studio Team

Our flagship:

DeepImmune

A subscription to innovation

Our Innovation Subscriptions give you royalty-free, unlimited access to all our current and forthcoming technology.

Chat with our team

Biotech Platforms

Royalty-free

Unlimited Access

Fixed Annual Fee

Case studies: How we help

There is no one-size-fits-all engagement with Alloy. We partner flexibly and creatively across each collaboration, activating our stable of platform technologies, discovery services, and company creation capabilities to meet our partners’ goals.

Make medicine together

ATX-Gx™ mice

The world’s first royalty-free humanized mouse platform for therapeutic antibody discovery.

Alloy Therapeutics humanized mouse antibody drug discovery platforms

Leveraged by a community of 100+ partners, the ATX-Gx is our foundational suite of highly immunocompetent transgenic mice for in vivo discovery. The growing suite of strains is engineered to drive the greatest potential diversity of unique human antibodies binding to your target of interest with broad epitopic coverage.

DEVELOPMENT

Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industrys standard dummy text ever since the 1500s.

GETTING STARTED

Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industrys standard dummy text ever since the 1500s.

OUR SUCCESS

Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industrys standard dummy text ever since the 1500s.

OUR ROADMAP

New Technology Platforms in Development

We are alway expanding our portfolio of innovative, enabling technologies. Platforms in development will support bispecifics and CAR Discovery, innovative combination therapeutics, and machine-learning enabled discovery.

Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industrys standard dummy text ever since the 1500s.

Targeting GPCRs with Alloy Antibody Discovery Services

Access the white paper

Thanks for your interest in our white paper, Targeting GPCRs with DeepImmune Antibody Discovery.

G protein-coupled receptors (GPCRs) play a central role in multiple physiological functions, from endocrine sensing to neurotransmission to chemotaxis of immune cells. This class has long been an attractive target for novel antibody drug discovery campaigns in multiple disease indications, but their unique nature produces many challenges for in vivo antibody discovery. In this white paper, we detail how our humanized mouse discovery platform, the ATX-Gx™, have been successfully utilized for GPCR-targeted antibody discovery, Alloy Antibody Discovery’s DeepImmune™ module builds on this robust in vivo discovery platform, coupling best-in-class immunogen production with multiple binder recovery approaches, and advanced machine-learning-based techniques for lead identification and optimization.

Keyway TCR Mimic Discovery Webinar

Access the webinar recording

I’d like more material about Keyway TCR Discovery

Thanks for your interest in our recent Keyway TCRm Discovery webinar, Increasing Target Specificity and Tackling Intracellular Targets for TCRm Therapeutics Development with Keyway’s TCRm Discovery Offering. In it, the team at the helm of our TCR mimic discovery campaigns shared:

1. An overview of common challenges to intracellular protein-targeting drug discovery
2. Keyway’s industry-leading solutions to TCRm/TCR-based therapeutic discovery including its proprietary specificity screening and high-quality pMHC complex antigen production capabilities
3. A case study featuring the discovery of a panel of highly specific, functional TCRm binders against an intracellular immuno-oncology target

Upon filling out this form, you will receive an email with a link to the webinar recording.

Our ecosystem model transforms drug discovery.

We are a biotechnology ecosystem company.

We empower discovery across 6 biologic modalities

ANTIBODIES

TCRS

GENETIC MEDICINES

PEPTIDES

CELL THERAPIES

DELIVERY

We make foundational drug discovery capabilities available to all.

Access to enabling technologies

ATX-Gx

Augmenting your capacity

DeepImmune

A subscription to innovation

Biotech Platforms

Royalty-free

Unlimited Access

Fixed Annual Fee

Case studies: How we help

Make medicine together

ATX-Gx™ mice

The world’s first royalty-free humanized mouse platform for therapeutic antibody discovery.

DEVELOPMENT

GETTING STARTED

OUR SUCCESS

OUR ROADMAP

New Technology Platforms in Development

READ MORE